Literature DB >> 27174282

Complete Genome Sequence of Vaccinia Virus Strain L-IVP.

Alexander N Shvalov1, Galina F Sivolobova2, Elena V Kuligina3, Galina V Kochneva4.   

Abstract

Most of the live vaccine doses of vaccinia virus donated to the Intensified Smallpox Eradication Programme after 1971 were prepared using the L-IVP strain. A mixture of three clones of the L-IVP strain was sequenced using MySEQ. Consensus sequence similarity with the vaccinia virus Lister strain is 99.5%.
Copyright © 2016 Shvalov et al.

Entities:  

Year:  2016        PMID: 27174282      PMCID: PMC4866859          DOI: 10.1128/genomeA.00372-16

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Due to its low pathogenicity, good cultivation properties, and ease of use for genomic manipulations, vaccinia virus is very promising and safe to use as a recombinant vaccine, gene transfer vector, and for other applications (1). The L-IVP vaccinia virus strain was derived by adapting the Lister strain of vaccinia virus to calf skin at the Institute for Research on Virus Preparations, Moscow, former Soviet Union (2). The L-IVP strain was used for the production of most of the vaccines donated to the Intensified Smallpox Eradication Programme after 1971 (3). Both nonrecombinant and recombinant variants of the L-IVP strain demonstrated high levels of tumor cell selectivity and oncolytic activity (4–6). The original wild-type vaccinia virus Lister strain (wt-Lister) as well as the L-IVP strain consist of numerous clones. Besides the currently presented sequence, there is only one recombinant strain derived from the vaccinia virus L-IVP strain that has been sequenced—GLV-1h68 (GenBank accession no. EU410304.1) (7). There are also complete genomes of 4 other variants of Lister strain clones, an averaged wt-Lister strain genome (GenBank accession no. AY678276.1), and 71 other complete sequences of vaccinia virus strains. Strain L-IVP was obtained from the State Collection of Viral and Rickettsial Disease Agents of the State Research Center of Virology and Biotechnology “Vector.” A mixture of three clones, derived from equal size plaques induced by the vaccinia virus L-IVP strain on a monolayer of CV-1 cells, was passed 6 times in cells of the same type and purified by centrifugation in sucrose density gradient. Strain L-IVP was sequenced on an Illumina Miseq platform using paired-end sequencing with 150-nt tag length and a mean insertion size of 385 nt. A consensus sequence was constructed using Mira v4.9.1 and Tmap v4.2.18. The length of the resulting sequence was 186,498 with an average coverage of 79×. The resulting sequence was annotated using GATU (8). There were ~1,000 single nucleotide polymorphisms (SNPs) and ~70 indels due to variations between the clones. Six of these indels lead to shifts of open reading frames (ORFs). One deletion leads to fusion of A39R and 169 ORFs. This fusion also occurs in several other vaccinia strains. The most noticeable difference is the deletion in two of three clones of the region 9,670 to 13,414 and the insertion of sequence CTATTACACCGGCTGAGT between C9L and C10L. Phylogenetic analysis using the maximum likelihood method with a bootstrap test of vaccinia strains showed clusterization of the L-IVP sequence within the Lister subfamily. There are no major changes in the genome structure of the L-IVP sequence and the nearest published sequence (wt-Lister). The overall difference between them is ~50 indels and ~530 mismatches (conserved genome sequence similarity is 99.5%.). The genome of L-IVP-derived GLV-1h68 (excluding recombinant inserts), another strain closely related to the L-IVP strain, differs from our consensus sequence much more. Besides the ~700 SNPs and ~50 small indels, in the GLV-1h68 genome there are extra copies of GL277 to GL283 ORFs and GL274 to GL276 ORFs are absent in the L-IVP strain genome. Sequencing was performed in the SB RAS Genomics Core Facility, Novosibirsk, Russia.

Nucleotide sequence accession number.

This genome sequence has been deposited in GenBank under the accession number KP233807.
  7 in total

1.  [Isolation of a recombinant vaccinia virus based on the LIVP strain inducing the surface antigen of the hepatitis B virus].

Authors:  A D Al'tshteĭn; L G Zakharova; V N Loparev; G V Pashvykina; S I Gorodetskiĭ
Journal:  Dokl Akad Nauk SSSR       Date:  1985

2.  Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma.

Authors:  Ivaylo Gentschev; Marion Adelfinger; Rafael Josupeit; Stephan Rudolph; Klaas Ehrig; Ulrike Donat; Stephanie Weibel; Nanhai G Chen; Yong A Yu; Qian Zhang; Martin Heisig; Douglas Thamm; Jochen Stritzker; Amy Macneill; Aladar A Szalay
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

3.  Genome Annotation Transfer Utility (GATU): rapid annotation of viral genomes using a closely related reference genome.

Authors:  Vasily Tcherepanov; Angelika Ehlers; Chris Upton
Journal:  BMC Genomics       Date:  2006-06-13       Impact factor: 3.969

Review 4.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

5.  Apoptin enhances the oncolytic properties of vaccinia virus and modifies mechanisms of tumor regression.

Authors:  Galina Kochneva; Evgeniy Zonov; Antonina Grazhdantseva; Anastasiya Yunusova; Galina Sibolobova; Evgeniy Popov; Oleg Taranov; Sergei Netesov; Peter Chumakov; Elena Ryabchikova
Journal:  Oncotarget       Date:  2014-11-30

6.  The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation.

Authors:  Qian Zhang; Chunguang Liang; Yong A Yu; Nanhai Chen; Thomas Dandekar; Aladar A Szalay
Journal:  Mol Genet Genomics       Date:  2009-08-22       Impact factor: 3.291

7.  Features of the Antitumor Effect of Vaccinia Virus Lister Strain.

Authors:  Evgeniy Zonov; Galina Kochneva; Anastasiya Yunusova; Antonina Grazhdantseva; Vladimir Richter; Elena Ryabchikova
Journal:  Viruses       Date:  2016-01-12       Impact factor: 5.048

  7 in total
  1 in total

1.  Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.

Authors:  Galina Kochneva; Galina Sivolobova; Anastasiya Tkacheva; Antonina Grazhdantseva; Olga Troitskaya; Anna Nushtaeva; Anastasiya Tkachenko; Elena Kuligina; Vladimir Richter; Olga Koval
Journal:  Oncotarget       Date:  2016-11-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.